openPR Logo
Press release

Hepatorenal Syndrome Therapeutics Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | Cumberland Pharmaceuticals, NOORIK BIOPHARMACEUTICALS LIMITED

07-26-2019 02:44 PM CET | Health & Medicine

Press release from: Pharma Proff

Hepatorenal Syndrome Therapeutics-Pharma Proff

Hepatorenal Syndrome Therapeutics-Pharma Proff

Hepatorenal syndrome (HRS) is a reversible functional renal impairment, that occurs in patients with advanced liver cirrhosis or those with fulminant hepatic failure. It is characterized by a marked reduction in glomerular filtration rate and renal plasma flow, in the absence of other causes of renal failure.

Download the sample report at: https://www.pharmaproff.com/request-sample/1030

The symptoms of hepatorenal syndrome are fatigue, abdominal pain, malaise, ascites, jaundice, splenomegaly, and hepatomegaly. There are two sub-types of this disease; type 1 and type 2 hepatorenal syndrome.

Get the detailed analysis at: https://www.pharmaproff.com/report/hepatorenal-syndrome-therapeutics-pipeline-analysis

Type 1 hepatorenal syndrome is a rapidly progressive renal failure, defined by doubling of initial serum creatinine to a level >2.5 mg/dl or by a 50% reduction in creatinine clearance to a level

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatorenal Syndrome Therapeutics Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | Cumberland Pharmaceuticals, NOORIK BIOPHARMACEUTICALS LIMITED here

News-ID: 1812631 • Views: 367

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Hepatorenal

Hepatorenal Syndrome Therapeutics Pipeline Analysis 2018 | Cumberland Pharmaceut …
Hepatorenal syndrome (HRS) is a reversible functional renal impairment, that occurs in patients with advanced liver cirrhosis or those with fulminant hepatic failure. It is characterized by a marked reduction in glomerular filtration rate and renal plasma flow, in the absence of other causes of renal failure. Download the sample report at: https://www.pharmaproff.com/request-sample/1030 The symptoms of hepatorenal syndrome are fatigue, abdominal pain, malaise, ascites, jaundice, splenomegaly, and hepatomegaly. There are two
Hepatorenal Syndrome Treatment Market Key Manufacturers, Development Trends And …
Hepatorenal syndrome or HRS is a medical condition characterized by progressive renal failure in patients with chronic liver disease or liver cirrhosis. It is a life-threatening and serious complication of cirrhosis. Patients suffering from HRS generally do not show any recognizable cause of kidney dysfunction as the kidneys themselves are not structurally damaged. It can be termed as “functional” form of kidney impairment. Patients suffering from hepatorenal syndrome generally does
Hepatorenal Syndrome Treatment Market Projected To Gain Significant Value By 202 …
Hepatorenal syndrome or HRS is a medical condition characterized by progressive renal failure in patients with chronic liver disease or liver cirrhosis. It is a life-threatening and serious complication of cirrhosis. Patients suffering from HRS generally do not show any recognizable cause of kidney dysfunction as the kidneys themselves are not structurally damaged. It can be termed as “functional” form of kidney impairment. Patients suffering from hepatorenal syndrome generally does
Hepatorenal Syndrome Treatment Market Lucrative Technological breakthroughs 2025
Hepatorenal syndrome or HRS is a medical condition characterized by progressive renal failure in patients with chronic liver disease or liver cirrhosis. It is a life-threatening and serious complication of cirrhosis. Patients suffering from HRS generally do not show any recognizable cause of kidney dysfunction as the kidneys themselves are not structurally damaged. It can be termed as “functional” form of kidney impairment. Patients suffering from hepatorenal syndrome generally does
Hepatorenal Syndrome Treatment Market Industrial Forecast On Global Industry Ana …
Hepatorenal syndrome or HRS is a medical condition characterized by progressive renal failure in patients with chronic liver disease or liver cirrhosis. It is a life-threatening and serious complication of cirrhosis. Patients suffering from HRS generally do not show any recognizable cause of kidney dysfunction as the kidneys themselves are not structurally damaged. It can be termed as “functional” form of kidney impairment. Patients suffering from hepatorenal syndrome generally does
Hepatorenal Syndrome Global Clinical Trials Review H2 2017
Summary:                                      ReportsWeb.com published “Hepatorenal Syndrome Global Clinical Trials Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: Publisher's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal